Fallopian tube disorder
MONDO:0002156A disease involving the fallopian tube.
Also known as: disease of fallopian tube, disease or disorder of fallopian tube, disorder of fallopian tube, fallopian tube disease, fallopian tube disease or disorder, fallopian tube disorder
374 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New cancer drug debio 0123 tested in early trial
Disease control TerminatedThis early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat tumors in early trial
Disease control TerminatedThis study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Ovarian cancer combo trial halted early
Disease control TerminatedThis study tested a new drug, CRLX101, combined with standard chemotherapy (paclitaxel) in 30 women with ovarian cancer that came back or didn't go away. The goal was to find the safest dose and see if the combination helped shrink tumors. The trial was terminated early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: NewLink Genetics Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer combo trial halted early after enrolling only 5 patients
Disease control TerminatedThis study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Ovarian cancer drug combo trial halted early
Disease control TerminatedThis phase 3 trial tested a combination of two targeted drugs, alpelisib and olaparib, against standard chemotherapy in 358 women with a tough-to-treat type of ovarian cancer that had stopped responding to platinum-based chemotherapy. The study only included women without a BRCA …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase: PHASE1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo for Hard-to-Treat cancers shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immune cells supercharged to fight ovarian cancer
Disease control TerminatedThis early-stage study tested a new way to treat ovarian, fallopian tube, or primary peritoneal cancer that had returned or stopped responding to standard treatments. Researchers took a type of white blood cell (monocytes) from each participant, stimulated them with two immune-bo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Measles virus takes on ovarian cancer in early trial
Disease control TerminatedThis phase 2 trial tested a genetically modified measles virus (MV-NIS) against standard chemotherapy in 17 women with ovarian, fallopian, or peritoneal cancer that no longer responded to platinum drugs. The virus was designed to infect and kill cancer cells while leaving healthy…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill shows promise against tough breast and ovarian cancers
Disease control TerminatedThis study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, but results help guide future …
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental ovarian cancer drug combo studied in early trial
Disease control TerminatedThis early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it …
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for tough ovarian cancer? trial tests smart drug vs chemo
Disease control TerminatedThis study tested a new drug called luveltamab tazevibulin (STRO-002) against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated …
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Ovarian cancer immune cells under microscope in terminated study
Knowledge-focused TerminatedThis study aimed to understand how immune cells in the blood, abdominal fluid, and tumor tissue change in women with advanced ovarian or fallopian tube cancer before and after chemotherapy. Researchers collected samples from 36 women to count different types of immune cells. The …
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Scientists tap cancer fluids for clues to better treatments
Knowledge-focused TerminatedThis study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about cancer biology, not to provide a direct treatment. Researchers hope these samples will help them understand how cancer grows and lead to better the…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC